Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aysha Habib

Internal Medicine Henrico, VA Medical Doctor

NPI 1407053713 CMS profile 62932

12320 W Broad St Ste 204, Henrico, VA 23233

Open in the dashboard

General payments

$7,290

467 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aysha Habib of Henrico, VA is reported in the CMS Open Payments database as having received $7,290 across 467 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $418 21
2024 General $158 9
2023 General $1,620 101
2022 General $2,276 139
2021 General $1,574 105
2020 General $372 25
2019 General $872 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aysha Habib
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Aysha Habib were reported at $418. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Aysha Habib Internal Medicine median Middle half National median
2019 $872 $159 $48–$570 $163
2020 $372 $119 $33–$402 $114
2021 $1,574 $135 $37–$521 $132
2022 $2,276 $141 $42–$496 $149
2023 $1,620 $149 $45–$519 $160
2024 $158 $154 $47–$537 $164
2025 $418 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,241 91 payments
  2. AbbVie, Inc. $1,130 74 payments
  3. Amgen Inc. $621 45 payments
  4. Lilly USA, LLC $619 45 payments
  5. AstraZeneca Pharmaceuticals LP $459 20 payments
  6. Pfizer Inc. $344 22 payments
  7. Abbott Laboratories $344 19 payments
  8. Biohaven Pharmaceutical Holding Company Ltd. $216 11 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $215 12 payments
  10. Sanofi-Aventis U.S. LLC $164 11 payments
  11. Other $1,936 117 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,283 466 payments
  2. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY $582 40 payments
  2. Ozempic $438 31 payments
  3. RYBELSUS $345 25 payments
  4. Prolia $341 25 payments
  5. FARXIGA $339 11 payments
  6. NURTEC ODT $328 16 payments
  7. EVENITY $323 23 payments
  8. TRULICITY $304 21 payments
  9. MOUNJARO $302 19 payments
  10. BREZTRI $272 6 payments
  11. Other $5,716 368 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 158 drugs

Part D claims

9,458

Median for Internal Medicine: 777

Drug cost

$707,516

Median for Internal Medicine: $73,373

Branded share of claims

21.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 147 $150,224
Jardiance Empagliflozin Brand 84 $114,760
Trulicity Dulaglutide Brand 74 $85,663
Linzess Linaclotide Brand 58 $46,697
Eliquis Apixaban Brand 35 $42,250
Wegovy Semaglutide Brand 19 $24,573
Januvia Sitagliptin Phosphate Brand 23 $21,524
Mounjaro Tirzepatide Brand 12 $20,924
Xarelto Rivaroxaban Brand 16 $17,301
Zenpep Lipase/Protease/Amylase Brand 13 $15,768

The 10 drugs with the highest cost, of 158 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$126,681

Of which drugs: $11,777

Medicare patients

395

Average age 75

Services billed

1,631

297 women, 98 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 46%
Osteoporosis 27%
Diabetes 26%
Ischemic heart disease 24%
Depression 19%
Cancer 15%
Chronic kidney disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 81 81 $6,627
Pcv20 vaccine im 90677 Office 11 11 $3,213

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

467 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record